Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07191717 · ClinicalTrials.gov registry record · Phase 2
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT07191717: Clinical Trial Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT07191717 is a Phase 2 study that has not yet begun recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07191717, a Phase 2 study, has not yet begun recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase II trial studies how well imlunestrant and abemaciclib work in treating patients with estrogen receptor positive (ER+) breast cancer who have tumor remaining in the blood following treatment (minimal residual disease). Estrogen can cause the growth of breast cancer cells. Imlunestrant lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Imlunestrant and abemaciclib may be effective in treating patients with ER+ breast cancer who have minimal residual disease.
Primary Outcome
Clearance of ctDNA is defined as having undetectable plasma ctDNA after completion of 12 cycles of adjuvant imlunestrant and abemaciclib. The rate of ctDNA clearance will be calculated as the percentage of all enrolled patients that have undetectable plasma after completion of adjuvant imlunestrant and abemaciclib (12 cycles or sooner if trial therapy is discontinued), and its Wilson 95% confidence interval will be reported.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- DRUG Abemaciclib
- PROCEDURE Radiologic Imaging Procedure
- DRUG Imlunestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2031-04-30 |
| Phase | Phase 2 |
What is known before NCT07191717 opens enrollment
NCT07191717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07191717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07191717 about?
NCT07191717 is a clinical study titled "Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial". This phase II trial studies how well imlunestrant and abemaciclib work in treating patients with estrogen receptor positive (ER+) breast cancer who have tumor remaining in the blood following treatment (minimal residual disease). Estrogen can cause the growth of breast cancer cells. Imlunestrant low...
What is the current status of trial NCT07191717?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2026-04-30. Estimated completion is 2031-04-30.
What interventions are being tested in trial NCT07191717?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Abemaciclib (DRUG), Radiologic Imaging Procedure (PROCEDURE), Imlunestrant (DRUG).
Who is sponsoring clinical trial NCT07191717?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07191717's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI